📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-31 18:55
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
13 announcements match the current filters (relevance ≥ 5).
Orchasp Board Approves ₹7.11 Cr Preferential Issue via Loan Conversion to Promoter Group
Orchasp Limited's Board approved the conversion of an outstanding loan into equity by issuing up to 1.50 crore equity shares of face value ₹2 each at ₹4.74 per share (including a premium of ₹2.74), aggregating to ₹7.11 crore. The allotment is being made on a preferential basis to promoter group entity Wahtulmsylh Limgawlat, which will hold a 4.15% stake post-issuance. The transaction value represents approximately 19.2% of the company's current market cap of ₹37 crore. The issuance is subject to shareholder approval at the AGM scheduled for September 30, 2026.
Confidence: HIGH
What changedThe company is converting a ₹7.11 crore promoter group loan into 1.50 crore fresh equity shares at an issue price of ₹4.74 per share.
Why it mattersThe conversion eliminates ₹7.11 crore in liabilities from the balance sheet and strengthens the net worth without cash outflow, priced above the current market price of ₹1.40.
Issue Size: ₹7.11 CrShares to be Issued: 1,50,00,000Issue Price per Share: ₹4.74Post-Issue Holding of Allottee: 4.15%Issue Size vs Market Cap: ~19.2%AGM Date: September 30, 2026
📅 Short termLikely to be viewed constructively by the market due to debt conversion at ₹4.74 per share compared to current market prices.
📈 Long termReduces debt obligations and reinforces promoter group commitment, though long-term performance hinges on turning around core IT operating profitability.
⚠ Risk flags
- Equity dilution of existing minority shareholders by 4.15%
- Shareholder approval is pending at the AGM
Key Highlights
Board approved issuance of 1,50,00,000 equity shares of face value ₹2 at ₹4.74 each (premium of ₹2.74).
Total fundraise/loan conversion size stands at ₹7.11 crore (~19.2% of ₹37 crore market capitalization).
Post-allotment, the promoter group entity will hold a 4.15% equity stake.
Shareholder approval will be sought at the AGM on September 30, 2026, with the relevant date set as August 28, 2026.
Board also approved the appointments of Sirisha Pattapurathi, Srinivasu Sunkara, and Ravi Prasad Muthyam as directors.
👀 What to Watch
Track the voting outcome of the upcoming AGM on September 30, 2026, for shareholder approval, followed by stock exchange in-principle listing approvals.
Orchasp Board approves ₹7.11 Cr loan conversion into equity shares at ₹4.74/share
Orchasp Limited has approved the conversion of an outstanding loan of ₹7.11 Cr due to promoter group entity Wahtulmsylh Limgawlat into equity shares on a preferential basis. The company will issue up to 1,50,00,000 equity shares (face value ₹2) at an issue price of ₹4.74 per share, including a premium of ₹2.74. The conversion amount represents ~19.2% of the company's current market capitalization (₹37 Cr) and will result in a 2.12% post-issue holding for the allottee. The transaction is subject to shareholder approval at the upcoming Annual General Meeting scheduled for September 30, 2026.
Confidence: HIGH
What changedBoard approved converting ₹7.11 Cr of promoter debt into 1.50 Cr equity shares at ₹4.74/share and appointed three new board directors.
Why it mattersExtinguishes ₹7.11 Cr in liabilities without cash outflow while expanding equity at a premium, improving balance sheet strength for a micro-cap company.
Total Conversion Amount: ₹7,11,00,000Shares to be Issued: 1,50,00,000Issue Price per Share: ₹4.74Conversion value vs Market Cap: ~19.2%Post-Issue Stake of Allottee: 2.12%AGM Date: September 30, 2026
📅 Short termPositive for sentiment as debt is resolved at a significant premium to current trading prices, pending shareholder approval at the AGM.
📈 Long termImproves balance sheet leverage, but sustainable re-rating will depend on core revenue growth and turnaround in operating profitability.
⚠ Risk flags
- Shareholder dilution from the issuance of 1.50 Cr fresh shares
- Related-party transaction involving promoter group entity
- Operational unprofitability (TTM OPM is negative at -13.5%)
Key Highlights
Conversion of promoter loan of ₹7.11 Cr into up to 1,50,00,000 equity shares on a preferential basis
Issue price set at ₹4.74 per share (Face Value ₹2 plus ₹2.74 premium), substantially above recent trading levels
Allottee post-conversion equity stake to stand at 2.12% (1.50 Cr shares)
Relevant date fixed as August 28, 2026 per SEBI ICDR regulations
Shareholder approval to be sought at the AGM on September 30, 2026
👀 What to Watch
Monitor the voting results of the AGM on September 30, 2026, and track subsequent regulatory in-principle and listing approvals for the preferential equity allotment.
Orchasp Board Approves Rs 7.11 Cr Loan Conversion to Equity at Rs 4.74/Share and Director Appointments
Orchasp Limited's Board approved the conversion of an outstanding promoter group loan into up to 1.50 crore equity shares at Rs 4.74 per share (face value Rs 2 plus premium of Rs 2.74), aggregating to Rs 7.11 crore on a preferential basis. The proposed issue represents approximately 19.2% of the company's current market cap (Rs 37 crore) and will result in a 2.12% post-issue shareholding for the allottee. Additionally, the Board approved the appointment of Mrs. Sirisha Pattapurathi as a Non-Executive Director and two Independent Directors for 5-year terms, subject to shareholder approval at the AGM scheduled for September 30, 2026.
Confidence: HIGH
What changedThe Board approved converting Rs 7.11 crore of promoter group debt into equity shares at Rs 4.74 each and reconstituted the board with three director appointments.
Why it mattersConverting debt into equity at a substantial premium to current market price improves net equity without cash outflow, though it introduces mild equity dilution.
Preferential Issue Size: Rs 7.11 CrIssue Price per Share: Rs 4.74Shares to be Issued: 1,50,00,000Issue Value vs Market Cap: ~19.2%AGM Date: September 30, 2026
📅 Short termMarket sentiment may view the debt conversion at Rs 4.74 (versus market price of Rs 1.40) constructively as a promoter commitment, subject to AGM clearance.
📈 Long termStrengthens equity capitalization and reduces debt liability, though long-term performance hinges on turnaround in operating margins and execution of its platform strategy.
⚠ Risk flags
- Equity dilution of 1.50 crore shares.
- Related-party nature of the loan conversion and board appointment.
- Pending shareholder and regulatory approvals.
Key Highlights
Approved conversion of Rs 7.11 crore promoter group debt into up to 1,50,00,000 equity shares on a preferential basis.
Issue price set at Rs 4.74 per share (Rs 2 face value + Rs 2.74 premium), well above the prevailing market price of Rs 1.40.
Post-allotment holding for the allottee (Wahtulmsylh Limgawlat) will be 1,50,00,000 shares, representing 2.12% of equity.
Appointed two Independent Directors (Srinivasu Sunkara and Ravi Prasad Muthyam) for 5-year terms alongside Non-Executive Director Sirisha Pattapurathi.
Annual General Meeting convened for September 30, 2026 to seek shareholder approval.
👀 What to Watch
Track shareholder voting results at the September 30, 2026 AGM for approval of the preferential issue, followed by subsequent in-principle exchange listing approvals.
Orchasp Limited Reports FY26 Net Profit of ₹1.05 Cr; Auditor Issues Qualified Opinion
Orchasp Limited returned to profitability in FY26, reporting a standalone net profit of ₹105.20 lakhs compared to a massive loss of ₹1,052.35 lakhs in FY25. However, the company's Q4 revenue dropped significantly to ₹161.26 lakhs from ₹700.96 lakhs year-on-year. A major concern for investors is the Auditor's Qualified Opinion, which highlights a ₹68.25 crore investment in a non-operational Portuguese subsidiary and the non-payment of statutory dues like TDS.
Key Highlights
Company turned profitable in FY26 with a net profit of ₹105.20 lakhs vs a loss of ₹1,052.35 lakhs in FY25.
Auditor issued a qualified opinion regarding the ₹6,825 lakh carrying value of a non-operational subsidiary facing cancellation of incorporation.
Q4 revenue from operations saw a sharp decline to ₹161.26 lakhs compared to ₹700.96 lakhs in the same quarter last year.
Auditors reported non-payment of Tax Deducted at Source (TDS) and other statutory dues up to March 31, 2026.
Trade receivables and payables outstanding for over 6 months lack confirmation, making recoverability uncertain.
👀 What to Watch
Investors should exercise extreme caution as the auditor's qualified opinion and statutory defaults (TDS) are significant red flags. The uncertainty surrounding the ₹68.25 crore investment impairment could materially impact future book value.
Orchasp Receives ₹12.59 Crore GST Demand for Import of Services
Orchasp Limited has received a Spot Memo from the GST Audit authority in Hyderabad for the period 2020-21 to 2023-24. The memo alleges non-payment of GST on the import of services under the Reverse Charge Mechanism (RCM). The quantified tax demand stands at ₹12.59 Crores, excluding interest and penalties which are yet to be determined. The company is currently evaluating the legal and financial implications of this notice.
Key Highlights
Tax demand of ₹12,58,59,446 (approx. ₹12.59 Crores) issued by the Commissioner of GST, Hyderabad.
The audit covers a four-year period from financial year 2020-21 to 2023-24.
Alleged violation involves non-payment of GST on Import of Services under Section 20 of the IGST Act.
Interest and penalties are yet to be quantified and will be additional to the base tax amount.
👀 What to Watch
Investors should exercise caution as the tax demand is significant and could impact the company's liquidity and profitability. Monitor for updates on whether the company contests the demand or makes a provision in its financial statements.
Orchasp's INDUSAYUSH Health Platform Approved for Apple App Store
Orchasp Limited has announced that its electronic health records (EHR) platform, INDUSAYUSH, was officially admitted to the Apple App Store on February 24, 2026. This milestone allows the company to distribute its digital health solution to a global iOS user base, enhancing its market reach. The approval follows the platform's development as a key digital asset for the company. Investors should note this as a positive step in the company's product scaling and digital health strategy.
Key Highlights
INDUSAYUSH electronic health records platform admitted to Apple App Store on February 24, 2026
The app is now available for global distribution to iOS users via the App Store
Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The move enables the company to leverage Apple's ecosystem for user engagement and monetization
👀 What to Watch
Investors should monitor the adoption rates and user feedback of the INDUSAYUSH app to gauge its potential impact on future revenue. Watch for updates on the platform's monetization strategy in upcoming quarterly earnings calls.
Orchasp Ltd Approves Q3 Results with Qualified Audit Opinion and Major Board Reconstitution
Orchasp Limited has approved its unaudited financial results for the quarter ended December 31, 2025, which notably received a qualified opinion from statutory auditors. The company is undergoing a significant board transition with the appointment of two new directors, including the sister of the current MD & CFO as a Non-Executive Director. Simultaneously, three Independent Directors are scheduled to exit the board between February and March 2026 following the completion of their tenures. This has led to a full reconstitution of the Audit, Nomination, and Stakeholders Relationship committees.
Key Highlights
Statutory auditors JMT & Associates issued a qualified opinion on the Q3 FY2025-26 financial results.
Mr. Srinivasu Sunkara appointed as Independent Director for a 5-year term effective February 10, 2026.
Ms. Sirisha Pattapurathi, sister of MD & CFO P. Chandra Sekhar, appointed as Non-Executive Non-Independent Director.
Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta) to cease office by March 6, 2026.
Board committees including Audit and Stakeholders Relationship reconstituted effective February 10, 2026.
👀 What to Watch
Investors should exercise caution and specifically review the 'qualified opinion' in the financial statements to understand the auditor's concerns. The simultaneous exit of three independent directors and the appointment of a promoter-related director warrant close monitoring of corporate governance standards.
Orchasp Ltd Appoints New Directors; Q3 FY26 Results Receive Qualified Auditor Opinion
Orchasp Limited has announced a significant board reshuffle, appointing Mr. Srinivasu Sunkara as an Independent Director for a five-year term and Ms. Sirisha Pattapurathi as a Non-Executive Director. These appointments coincide with the upcoming departure of three Independent Directors between February and March 2026. Notably, the company's Q3 FY26 financial results were approved but received a qualified opinion from the statutory auditors, JMT & Associates. Investors should note that Ms. Pattapurathi is the sister of the current Managing Director and CFO.
Key Highlights
Appointment of Mr. Srinivasu Sunkara as Independent Director for a 5-year term ending February 2031.
Ms. Sirisha Pattapurathi appointed as Non-Executive Director; she is the sister of the MD & CFO.
Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Reddy, and Mr. Sai Vegunta) to exit by March 6, 2026.
Statutory auditors issued a qualified opinion on the unaudited financial results for the quarter and nine months ended December 31, 2025.
Board committees, including Audit and Nomination, were reconstituted effective February 10, 2026.
👀 What to Watch
Investors should carefully review the specific reasons behind the auditor's qualified opinion in the Q3 results to assess financial transparency risks. Monitor how the significant turnover in independent directors affects the company's corporate governance standards.
Orchasp Ltd Q3 FY26 Results Approved; Board Reconstituted Amid Auditor Qualification
Orchasp Limited has approved its Q3 FY26 financial results, which notably received a qualified opinion from statutory auditors JMT & Associates. The company is undergoing a major board transition with the appointment of Mr. Srinivasu Sunkara as an Independent Director and Ms. Sirisha Pattapurathi as a Non-Executive Director. This follows the upcoming cessation of three independent directors—Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta—by March 2026. Consequently, the Audit and other board committees have been reconstituted to align with the new leadership structure.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Statutory auditors issued a qualified opinion on the financial statements, indicating potential accounting concerns.
Appointed Mr. Srinivasu Sunkara as Independent Director for a five-year term ending February 2031.
Ms. Sirisha Pattapurathi, sister of the MD & CFO, appointed as a Non-Executive Non-Independent Director.
Three Independent Directors to step down by March 2026 upon completion of their respective terms.
👀 What to Watch
Investors should exercise caution and investigate the specific nature of the auditor's qualified opinion. The significant turnover in independent directors and the appointment of a promoter relative to the board suggest a need for heightened monitoring of corporate governance.
Orchasp's INDUSAYUSH Health Platform Now Live on Google Play Store
Orchasp Limited has announced the successful admission of its electronic health records (EHR) platform, INDUSAYUSH, on the Google Play Store effective December 31, 2025. This launch represents a key milestone in the company's digital healthcare strategy, providing broader access to its services for Android users. The availability of the app is expected to facilitate user acquisition and enhance the visibility of the company's healthcare technology offerings. Investors should note this as a positive step toward scaling their digital product portfolio.
Key Highlights
INDUSAYUSH electronic health records platform admitted to Google Play Store on December 31, 2025
Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The app is now publicly accessible for download, marking a transition from development to market availability
Move aims to strengthen the company's footprint in the digital health and EHR management sector
👀 What to Watch
Investors should monitor the app's download growth and user reviews to gauge market adoption. It is also important to look for upcoming management commentary regarding the monetization plan for the INDUSAYUSH platform.
Orchasp Allots 2.68 Crore Equity Shares at Rs 3.20 to Settle Debt
Orchasp Limited has approved the allotment of 2,68,75,000 equity shares on a preferential basis at an issue price of Rs 3.20 per share. These shares are being issued to Mrs. P. Rajeswari, the legal heir of the company's former Chairman & CEO, Mr. P.C. Pantulu. The allotment serves to convert outstanding loan amounts into equity, effectively reducing the company's debt liabilities. While this move results in equity dilution, it improves the company's balance sheet by settling debt without cash outflow.
Key Highlights
Allotment of 2,68,75,000 equity shares with a face value of Rs 2 each.
Preferential allotment price set at Rs 3.20 per share.
Shares issued to settle outstanding loan amounts of the late ex-Chairman & CEO.
Total transaction value for debt-to-equity conversion is approximately Rs 8.6 crore.
Board has authorized the Managing Director to proceed with listing and trading permissions.
👀 What to Watch
Investors should view the debt reduction as a positive for the company's financial health, though they should be mindful of the resulting equity dilution. Monitor the company's upcoming quarterly results to see the impact of reduced interest burdens.
Orchasp receives in-principle approval for equity share issue
Orchasp Limited has received in-principle approval from the NSE for issuing equity shares of ₹2 each under preferential terms. The approval is subject to the company fulfilling several conditions, including filing the listing application promptly and complying with regulations from SEBI, RBI, and MCA. The NSE has also advised Orchasp to strengthen internal controls to monitor trading by allottees and ensure compliance with SEBI (ICDR) Regulations. Investors should monitor the company's progress in fulfilling these conditions and ensure compliance with regulatory requirements.
Key Highlights
In-principle approval for issue of Equity shares of Rs. 2/- each
Compliance with SEBI (LODR) Regulations, 2015
Compliance with Companies Act, 1956 / Companies Act, 2013
Company advised to strengthen internal controls before allotment of securities
👀 What to Watch
Investors should monitor Orchasp's compliance with the conditions set by NSE and SEBI. Watch for the filing of the listing application and adherence to regulatory guidelines.
Orchasp to Incorporate Wholly-Owned Subsidiary 'Orchasp Inc' in USA
Orchasp Limited is expanding its operations by incorporating a wholly-owned subsidiary named "Orchasp Inc" in the USA. This decision follows a board evaluation that found the cost of reviving the dormant Cybermate Infotek Limited Inc subsidiary to be higher than creating a new one. The new subsidiary will focus on marketing the indusayush health care platform and enabling the mobile app on android and ios playstore. The proposed share capital for Orchasp Inc is 10,000 shares at USD 1 each, totaling USD 10,000.
Key Highlights
Incorporating a wholly-owned subsidiary in USA named “Orchasp Inc”.
Proposed share capital of 10,000 Shares of USD 1 each.
Total investment of USD 10,000 in the new subsidiary.
👀 What to Watch
Investors should monitor the performance of the new subsidiary and its impact on Orchasp's overall revenue and profitability. Keep an eye on the adoption and market penetration of the indusayush platform in the US market.
